BridGene Biosciences, Inc., a San Jose, CA-based biotechnology company leveraging a proprietary chemoproteomic platform to discover and develop small-molecule drugs for high-value, traditionally undruggable targets, closed a $38.5m Series B financing.
The round was led by Lapam Capital, Junson Capital and Dyee Capital.
The company intends to use the funds to develop its pipeline project, a covalent TEAD inhibitor, as well as a few other undisclosed first-in-class oncology pipeline projects, which were initiated based on discoveries using the IMTAC™ platform.
The company intends to use the funds to further develop its chemoproteomic platform IMTAC™, which enables the screening of small molecules against the whole proteome or against a prioritized target in live cells to discover drug candidates for high value and traditionally undruggable targets that drive diseases, including cancers.
Led by Ping Cao, Ph.D., CEO and co-founder, BridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat diseases. By using its proprietary chemoproteomics platform, IMTAC™, the company can screen small molecules against proteins in live cells to discover drug candidates for high value and traditionally undruggable targets. BridGene’s technology allows it to perform IMTAC™ screening for both covalent and non-covalent molecules, target different amino acids and discover new targets for disease treatments by deconvoluting phenotypic screening hits. The company is advancing a diversified pipeline of first-in-class drugs for targets in multiple disease areas.
FinSMEs
28/07/2022